Viatris Inc. announced an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. for sotagliflozin in all global markets outside of the United States and Europe. This agreement leverages Viatris's expertise in cardiovascular diseases and its extensive global healthcare gateway.
Under the terms of the agreement, Viatris will make an upfront payment of $25 million to Lexicon. The deal also includes potential contingent payments, such as regulatory milestones, sales milestones, and tiered royalties ranging from low-double-digit to upper-teens on annual net sales.
Viatris will assume responsibility for all regulatory and commercialization activities for sotagliflozin in the licensed territories. Lexicon Pharmaceuticals will be responsible for providing the clinical and commercial supply of the drug to Viatris.
Sotagliflozin received U.S. Food and Drug Administration approval in May 2023 for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This strategic transaction is expected to expand Viatris's innovative portfolio and drive durable revenue growth by addressing significant unmet medical needs in new regions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.